*Purpose: To explore the clinical value of low-dose aspirin (100mg) and statins (10 ~ 20mg) in the prevention of transplant renal artery stenosis (TRAS).

*Methods: A total of 266 kidney transplant patients were divided into three groups according to whether they had taken low-dose aspirin or statins from January 2018 to December 2020, including 93 cases in the aspirin group (A), 69 cases in the statin group (S) and 104 cases in the control group (C). Low-dose aspirin should be taken orally for more than 3 months. Statins should be taken orally after surgery due to the formation of arterial plaque. All patients were treated with thymoglobuline before surgery, and the post-operative immunosuppressive maintenance regimen was CNI+ mycophenolate mofetil/mycophenolate sodium + prednisone. SPSS 17.0 software was used for statistical analysis.

*Results: There were no significant differences in gender, age, primary disease, concomitant disease, viral infection, dialysis time, immunosuppressive drugs, number of arterial vessels, vascular anastomosis and transplantation type among the three groups (P > 0.05). 11 patients (11.83%), 18 patients (26.09%) and 20 patients (19.23%) were primary diagnosed TRAS in group A, group S and group C, respectively. There were significant differences between group A and group S (χ²=5.48, P=0.019). While there was no significant difference between the other two groups (P > 0.05). There were 2 patients (2.15%), 8 patients (11.59%) and 12 patients (11.54%) in group A, group S and group C, respectively. There were statistically significant differences between group A and T (χ²=4.578, P=0.032), group A and group C (χ²=5.210, P=0.022). But there was no statistical difference between group S and group C (P > 0.05).

*Conclusions: Low-dose aspirin plays a key role in the prevention of TRAS and is significantly effective in patients without arterial plaque formation.

« Back to 2022 American Transplant Congress